Atlas Trials

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Clinical trial NCT05626400 · RECRUITING

Trial details

NCT number
NCT05626400
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Start date
2022-08-29
Primary completion
2027-10-30
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.